Le Lézard
Classified in: Science and technology
Subjects: Contract/Agreement, Product/Service

Cognyte Strengthens Relationship with National Intelligence Organization, Secures Approximately $5 Million Follow-On Order


Cognyte Software Ltd. (NASDAQ: CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced that it received an approximately $5 million additional order from a national intelligence organization in the Europe-Middle East-Africa (EMEA) region, for its solution that helps identify and prevent threats during operations.

Including this latest order, Cognyte has received three orders from this customer over the past year, serving as a testament to the superiority of the company's technology. Through ongoing delivery of effective results, Cognyte's solutions enhance operational efficiency and create substantial value for the customer's operational teams.

"We have consistently delivered value to this customer with solutions that align to their evolving needs," said Efi Nuri, Cognyte's chief revenue officer. "The effectiveness of our technology, coupled with our ability to provide solutions that address the growing challenges our global customers face, continues to open opportunities for driving growth. We are pleased to expand our partnership with this customer and look forward to further collaboration."

About Cognyte Software Ltd.

Cognyte Software Ltd. is a global leader in investigative analytics software that empowers a variety of government and other organizations with Actionable Intelligence for a Safer Worldtm. Our open interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making. Hundreds of customers rely on our solutions to accelerate and conduct investigations and derive insights, with which they identify, neutralize, and tackle threats to national security and address different forms of criminal and terror activities. Learn more at www.cognyte.com.


These press releases may also interest you

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...



News published on and distributed by: